Source link : https://www.newshealth.biz/health-news/adjuvant-atezolizumab-plus-bevacizumab-strike-out-in-hcc/
The initial results of the IMbrave050 trial raised hopes that an effective adjuvant regimen for hepatocellular carcinoma (HCC) might finally have arrived. Patients with HCC treated with a combination of the immune checkpoint inhibitor atezolizumab and angiogenesis inhibitor bevacizumab after resection or ablation showed a 28% improvement in recurrence-free survival at a medium follow-up of […]
Author : News Health
Publish date : 2024-09-17 14:19:14
Copyright for syndicated content belongs to the linked Source.
Categories